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Case Reports

A case series of primary cutaneous B-cell lymphomas
with atypical presentations: diagnostic and therapeutic
challenges
Primary cutaneous B-cell lymphomas (PCBCL) are
defined as B-cell lymphomas of the skin without nodal,
bone marrow, or visceral involvement at the time of diagnosis.1 They represent approximately 25% of primary
cutaneous lymphomas.1,2 The histopathological diagnosis
of PCBCL can be challenging in certain instances in
which overlapping features are present. Nevertheless,
identification of the correct subtype of PCBCL is imperative for determining the prognosis and avoiding inappropriate aggressive treatments which could lead to unnecessary morbidity.3 Here we present a series of three cases
that highlight the distinguishing features between two
subtypes of PCBCL.
The first case was a 57-year-old African American man
with multiple pruritic nodules on his abdomen that
appeared and rapidly progressed in size 6 months prior to
presentation (Figure 1A). Review of systems was negative for pain, weight loss, night sweats or fever. Blood
flow cytometry analysis was normal, and positron emission tomography (PET) scan was negative for metabolically active lymph nodes or systemic disease. Skin biopsy
demonstrated sheets of large atypical lymphoid aggregates with centroblast morphology extending into the
entire thickness of the dermis with an accompanying significant reactive small-sized lymphocytic infiltrate (Figure
1B). The large cells expressed CD20 and BCL6 but were
negative for CD10, BCL2, and MUM-1 on immunostaining (Figure 1D-H). Ki67 stain showed a proliferation rate
of 30-40%. B-cell receptor clonality assay (ClonoSeq)
identified two dominant immunoglobulin heavy chain
sequences. An initial diagnosis of diffuse large B-cell lymphoma (DLBCL) was considered, but a complete
histopathological review with clinical correlation led to a
final diagnosis of primary cutaneous follicle center lymphoma (PCFCL) with diffuse pattern. Three large lesions
were excised and local radiation therapy provided total
regression of the rest of the abdominal tumors without
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recurrence to date (2 years).
The second case was an 83-year-old Caucasian male
presenting with an erythematous, asymptomatic growth
on the forehead that had increased in size to 6 x 7 cm
over 6 months (Figure 2A). The patient had no systemic
symptoms of fever, night sweats, weight loss, or lymphadenopathy. Punch biopsy of the lesion demonstrated
a dense lymphocytic neoplasm composed of centroblasts
and immunoblasts positive for CD10, CD20, and BCL6
but negative for MUM1. Small-sized reactive lymphocytes were BCL2-positive (Figure 2B, D-H).
Immunoglobulin heavy chain gene-rearrangement studies revealed a monoclonal population. Blood flow cytometry analysis and PET scan were negative for blood or
systemic involvement. This case was also initially diagnosed as DLBCL, but a secondary histopathological
review combined with clinical correlation led to a diagnosis of PCFCL with diffuse pattern. Radiation therapy
provided complete regression of the tumor without
recurrence to date (1.5 years).
The third case was a 72-year-old man with a history of
chronic kidney disease and heart failure who presented
with a tender pink tumor on his scalp that abruptly
appeared as a small papule but rapidly grew in size to 4
x 4 cm over 1 month (Figure 3A). His clinical history was
negative for fever, lymphadenopathy, fatigue, night
sweats, and systemic symptoms. Punch biopsy revealed
a sheet-like diffuse dense infiltrate composed of cells
with immunoblastic morphology and high mitotic activity (Figure 3B). The atypical lymphocytes stained positive
for CD10, CD20, BCL2, BCL6, and MUM1 (Figure 3D-H)
with a more than 80% proliferative population based on
Ki-67 positivity. Fluorescent in-situ hybridization (FISH)
was positive for a BCL6 gene rearrangement (18% of
nuclei) and negative for rearrangement of MYC, CCND1,
and BCL2. A dominant immunoglobulin heavy chain
sequence present in 99% of all nucleated cells was identified by immunosequencing (ClonoSeq). PET scan
revealed a hypermetabolic scalp lesion with no evidence
of lymph node or systemic involvement, and blood flow
cytometry analysis was normal. The patient was diagnosed with primary cutaneous diffuse large B-cell lym-

C

B

E

F

G

H

Figure 1. Primary cutaneous follicle center lymphoma identified by various features. (A) Three firm, ill-defined, pink tumors, 2 to 3 cm in size, with surrounding
erythematous plaques and significant induration on the mid abdomen. (B, C) Dense lymphocytic infiltrate of small to medium sized lymphocytes with condensed
nuclei (hematoxylin & eosin: [B] 40x, [C] 100x) that are (D) CD10-negative, (E) CD20-positive, (F) BCL2-negative, (G) BCL6-positive, and (H) MUM1-negative.
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Figure 2. A different presentation of primary cutaneous follicle center lymphoma. (A) A single firm erythematous tumor on the right of the forehead. (B, C)
Dense infiltrate of medium-sized centroblasts and immunoblasts in the dermis (hematoxylin & eosin: [B] 40x, [C] 100x) that are (D) CD10-positive, (E) CD20positive, (F) BCL2-negative on large cells and BCL2-positive on reactive cells, (G) BCL6-positive, and (H) MUM1-negative.

phoma, leg type (PCDLBCL, LT). Combination
chemotherapy with rituximab plus cyclophosphamide,
doxorubicin, vincristine, and prednisone (R-CHOP) was
not initiated due to the patient’s poor ejection fraction
(48%). Instead, given his comorbidities and life expectancy, he received radiation therapy with complete resolution of the lesion, confirmed with PET scan. Due to his
aggressive diagnosis, the patient was closely monitored
by oncology without recurrence for 2 years until he died
from a cardiac arrest due to his comorbidities.
The three cases presented here highlight the challenge
of distinguishing between PCFCL and PCDLBCL-LT, two
of the three main subtypes of PCBCL. The first two cases
of PCFCL were originally diagnosed as DLBCL without
specification. The correct diagnosis of diffuse PCFCL was
made after a secondary histological consultation along
with clinical correlation.4,5 The third case illustrates the
fact that a PCDLBCL, LT can present on the scalp.
For the first two cases, the absence of a follicular pattern and diffuse sheets of atypical large cells gave an initial impression of DLBCL while the lack of expression of
MUM1 and the presence of a reactive infiltrate clearly
pointed to the diagnosis of PCFCL.5,6 Although all cases
showed a diffuse infiltrate on histology, their histomorphology, immunophenotype, pattern of molecular aberration on FISH analysis, and clinical presentation distinguished the correct diagnosis. This underscores the
importance of recognizing PCFCL with diffuse pattern to
avoid overcalling DLBCL and the resulting unnecessary
aggressive treatment.
Histomorphology should be investigated in detail to
arrive at the correct diagnosis among cases of PCBCL.3
Although diffuse sheets of cells were seen in all cases, a
close evaluation of cellular morphology clearly distinguishes DLBCL from other subtypes. Large cells with
multiple mitotic figures and nuclear atypia in PCDLBCL,
LT contrast directly with the smaller cells and condensed
nuclei seen in PCFCL cases (Figures 1C, 2C, and 3C).6
Immunohistochemistry is an essential tool in diagnosing subtypes of PCBCL. MUM-1 positivity precludes
PCFCL and must be investigated before making a diagnohaematologica | 2022; 107(4)

sis of any subtype of PCBCL. BCL-2 is not expressed by
malignant cells in PCFCL, but it may be present in reactive T cells.3 In the second case of the series presented
here, BCL-2 was originally called positive but upon further evaluation it was clear that only reactive cells
expressed BCL-2. FISH studies can be utilized in cases of
PCDLBCL, LT, and we found a positive BCL6 gene
rearrangement in our case.
Overall, these cases demonstrate the architectural, histomorphological, and immunohistochemical features
that can distinguish PCFCL from PCDLBCL, LT and highlight the diagnostic challenges that arise as a result of
overlapping characteristics. The clinical impact of this
overlap is most acutely felt in PCDLBCL, LT, because of
its more aggressive course and the fact that radiation
therapy alone is generally considered inadequate.7,8
While there is currently no evidence-based standard of
care, most cases of PCDLBCL, LT are treated as systemic
DLBCL, with R-CHOP chemoimmunotherapy, often
with central nervous system prophylaxis, due to the high
risk of central nervous system dissemination.9 The addition of radiation therapy to chemoimmunotherapy was
found to be important in a recent case series.10 Despite
historical data showing that the outcomes of patients
with PCDLBCL,LT have improved since the introduction
of modern chemoimmunotherapy, outcomes remain relatively poor.11 In addition, many patients are unfit for
chemotherapy, due to age or comorbidities. In the cohort
reported by Grange et al. in 2014 about 50% of the
patients were older than 80 years. At the moment, frontline radiation therapy, especially for localized, unifocal
disease, is an acceptable option for elderly and frail
patients, and some patients, including the third case presented here, have durable responses and long-progression free survival.12,13
The clinical and histological findings of B-cell lymphomas can vary widely. The clinical picture in the first
case reminds readers that it is possible to have multiple
lesions in PCFCL, including multifocal lesions, although it
is often thought to present as a solitary lesion. The second case emphasizes that histological and immunohisto1015
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Figure 3. Primary cutaneous diffuse large B-cell lymphoma, leg type is defined by features seen in this figure. (A) A well-defined tumor on the left parietal scalp
with (B, C) diffuse proliferation of large polygonal lymphocytes with high mitotic activity, large nuclei, and little cytoplasm (hematoxylin & eosin: [B] 40x, [C] 100x)
that are (D) CD10-positive, (E) CD20-positive, (F) BCL2-positive, (G) BCL6-positive and (H) MUM1-positive.

chemical results must be assessed together, without relying on one over the other. Case three cautions physicians
that PCDLBCL, LT can occur elsewhere on the body
while having overlapping histological features with
PCFCL. Due to the complexity of cutaneous lymphomas,
it is imperative for physicians to work together in a multidisciplinary team with dermatology, oncology, dermatopathology and radiation oncology in order to provide the best care for these patients.
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